U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 1O-KSB
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2003.
OR
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to ____________
Commission file number 1-10526
UNITED-GUARDIAN, INC.
(Name of small business issuer in its charter)
Delaware 11-1719724
-------------------------------- ---------------------------------
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
230 Marcus Blvd., Hauppauge, NY 11788
--------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code: (631) 273-0900
--------------
Securities registered pursuant to Section l2(b) of the Exchange Act: None
Title of each class Name of each exchange on which registered
------------------------------------ -----------------------------------------
Common Stock, $.10 par value American Stock Exchange
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or l5(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]
Cover Page 1 of 2 Pages
Indicate by check mark if there is no disclosure herein of delinquent filers
pursuant to Item 405 of Regulation S-B, and if, to the best of registrant's
knowledge, no disclosure will be contained in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [X]
The Registrant's revenues for the fiscal year ended December 31, 2003 were
$11,157,423.
On March 1, 2004 the aggregate market value of the Registrant's Common
Stock (based upon the closing sales price of such shares on the American Stock
Exchange as reported in The Wall Street Journal) held by non-affiliates of the
Registrant was approximately $17,818,997. (Aggregate market value has been
estimated solely for the purposes of this report. For the purpose of this report
it has been assumed that all officers and directors of the Registrant, as well
as all stockholders holding 10% or more of Registrant's stock, are affiliates of
the Registrant. The statements made herein shall not be construed as an
admission for determining the affiliate status of any person.)
As of March 1, 2004 the Registrant had issued 4,984,739 shares of Common
Stock, $.10 par value per share ("Common Stock"), of which 4,922,539 shares were
outstanding and 62,200 held as Treasury stock as of that date.
Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]
DOCUMENTS INCORPORATED BY REFERENCE:
Certain information required by Part III (portions of Item 9, as well as
Items 10 and 11) is incorporated by reference to the Registrant's definitive
proxy statement (the "2004 Proxy Statement") in connection with its 2004 annual
meeting of stockholders, which is to be filed no later than April 20, 2004 with
the Securities and Exchange Commission pursuant to Regulation 14A of the
Securities Exchange Act of 1934, as amended.
Cover Page 2 of 2 Pages
This annual report on Form 10-KSB contains both historical and
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, which provides a safe harbor for forward-looking
statements by the Registrant about its expectations or beliefs concerning future
events, such as financial performance, business prospects, and similar matters.
The Registrant desires to take advantage of such "safe harbor" provisions and is
including this statement for that express purpose. Words such as "anticipates",
"believes", "expects", "intends", "future", and similar expressions identify
forward-looking statements. Any such "forward-looking" statements in this report
reflect the Registrant's current views with respect to future events and
financial performance, and are subject to a variety of factors that could cause
Registrant's actual results or performance to differ materially from historical
results or from the anticipated results or performance expressed or implied by
such forward-looking statements. Because of such factors, there can be no
assurance that the actual results or developments anticipated by the Registrant
will be realized or, even if substantially realized, that they will have the
anticipated results. The risks and uncertainties that may affect Registrant's
business include, but are not limited to: economic conditions, governmental
regulations, technological advances, pricing and competition, acceptance by the
marketplace of new products, retention of key personnel, the sufficiency of
financial resources to sustain and expand Registrant's operations, and other
factors described in this report and in prior filings with the Securities and
Exchange Commission. Readers should not place undue reliance on such
forward-looking statements, which speak only as of the date hereof, and should
be aware that except as may be otherwise legally required of Registrant,
Registrant undertakes no obligation to publicly revise any such forward-looking
statements to reflect events or circumstances that may arise after the date
hereof.
PART I
Item 1. Description of Business
(a) General Development of Business
The Registrant is a Delaware corporation that conducts research, product
development, manufacturing and marketing of cosmetic ingredients, personal and
health care products, pharmaceuticals, and specialty industrial products. The
Registrant also distributes an extensive line of fine organic chemicals,
research chemicals, test solutions, indicators, dyes and reagents through a
wholly owned subsidiary, Eastern Chemical Corporation ("Eastern").
The Registrant's predecessor, United International Research Corp. (name
later changed to United International Research, Inc.), was founded and
incorporated in New York in 1942 by Dr. Alfred R. Globus, the Registrant's
Chairman and Chief Executive Officer. On February 10, 1982, a merger took place
between the Registrant and Guardian Chemical Corp. ("GCC"), an affiliate of the
Registrant, whereby GCC was merged into the Registrant and the name was changed
to United-Guardian, Inc. On September 14, 1987, United-Guardian, Inc. (New York)
was merged with and into United-Guardian, Inc., a newly incorporated Delaware
corporation formed for the purpose of changing the domicile of the Registrant.
The Registrant operates in two business segments:
(1) The Guardian Laboratories Division ("Guardian") conducts research,
product development, manufacturing and marketing of cosmetic ingredients,
personal and health care products, pharmaceuticals, and specialty industrial
products. The Research and Development Department of Guardian engages in
research and development in the fields of cosmetics, health care products, and
specialty industrial chemical products, for the purpose of developing new
products, and refining existing products that will be marketed or licensed by
Guardian. Many of the products manufactured by Guardian, particularly its
LUBRAJEL(R) line of products, are marketed worldwide through a network of
distributors, and are currently used by many of the major multinational cosmetic
companies.
Guardian presently has a broad range of products, some of which are
currently marketed, some of which are marketable but are not currently marketed
by the Registrant, and some of which are still in the developmental stage. Of
the products being actively marketed, the two largest product lines are the
LUBRAJEL line of cosmetic ingredients, which accounted for approximately 67% of
the Registrant's sales in 2003, and its RENACIDIN(R) IRRIGATION, a
pharmaceutical product that accounted for approximately 16% of the Registrant's
sales in 2003. The Registrant actively seeks other companies as potential
marketers for its products, particularly for those products that are not yet
being actively marketed by the Registrant.
(2) Eastern distributes an extensive line of fine organic chemicals,
research chemicals, test solutions, indicators, dyes, stains, and reagents. The
Registrant's business activities and marketing efforts over the past several
years have focused increasingly on the Guardian division, which the Registrant
believes has greater growth potential. Over the past several years the
Registrant has significantly reduced Eastern's inventory levels in order to make
the subsidiary more marketable in the event Registrant decides to sell the
Eastern operation at some future date. This has resulted in some loss of sales
on items that previously would have been in inventory, but for the most part
Eastern's sales have not been significantly impacted by this reduction in
inventory. Registrant believes that if the Registrant were to sell Eastern, the
loss of revenue from that subsidiary would not significantly impact the
Registrant's net income.
Paragon Organic Chemicals, Inc. ("Paragon") is a wholly owned subsidiary of
the Registrant. It has no assets or sales of its own, and its sole function is
to act as a purchasing arm of the Registrant.
(b) Narrative Description of Business
Guardian Laboratories Division
Guardian conducts research, product development, manufacturing and
marketing of many different cosmetic ingredients, personal and health care
products, pharmaceuticals, and specialty industrial products, all of which are
developed by the Registrant, and many of which have unique properties. The
products manufactured by Guardian are marketed through marketing partners,
distributors, direct advertising, mailings, and trade exhibitions. Guardian's
proprietary cosmetic ingredients are sold through marketing partners and
distributors and are incorporated into products marketed by many of the major
international cosmetic companies. Many of Guardian's products are marketed
through collaborative agreements with larger companies. The pharmaceutical
products are sold to end users primarily through drug wholesalers. These sales
include indirect sales to the Veteran's Administration and other government
agencies. There are also a small number of direct sales to hospitals and
pharmacies.
During 2003, Guardian's sales accounted for approximately 90% of
Registrant's total product sales.
Guardian's products are sold under trademarks or trade names owned by the
Registrant. The marks for the most important products, LUBRAJEL and RENACIDIN,
are registered as trademarks in the United States Patent and Trademark Office
("Patent Office"). In 2003 sales from these two product lines accounted for
approximately 91% of Guardian's sales, and 83% of the sales of the Registrant as
a whole.
LUBRAJEL
LUBRAJEL is a line of nondrying water-based moisturizing and lubricating
gels that have applications in the cosmetic industry primarily as a moisturizer
and as a base for other cosmetic products, and in the medical field primarily as
a lubricant. In the cosmetic industry it is used primarily as a stable gel for
application around the eyes and on the face and as an ingredient in skin creams
and moisturizers, makeup, body lotions, hair preparations, salves, and
ointments. As a medical lubricant it has been used on prelubricated enema tips
and thermometers, and as a lubricant for catheters. During 2003, sales of
LUBRAJEL products increased 34% from $5,582,293 in 2002 to $7,476,719 in 2003.
Sales of LUBRAJEL products represented 74% of Guardian's sales and 67% of the
sales of the Registrant as a whole. The most important product in the LUBRAJEL
line in 2003 was LUBRAJEL CG, the original form of LUBRAJEL, the sales of which
increased 6% from $1,931,408 in 2002 to $2,041,015 in 2003. Sales of the second
largest revenue producer in the Lubrajel line, LUBRAJEL OIL, more than doubled
in 2003, increasing from $610,997 in 2002 to $1,434,502 in 2003, an increase of
135%, eclipsing the company's second largest revenue producer from the prior
year, LUBRAJEL MS, which still increased 16% from $1,188,170 in 2002 to
$1,373,648 in 2003. The Registrant believes that the significant increase in
sales of its LUBRAJEL products in 2003 was the result of increased market
penetration resulting from the continuing marketing efforts of Registrant's
marketing partners, particularly ISP. A significant portion of the increase in
sales of LUBRAJEL OIL was attributable to a new product introduction containing
LUBRAJEL OIL by a major global cosmetics company.
Registrant believes that its ability to increase sales of its LUBRAJEL
products will depend on (a) the ability of Registrant's marketing partners and
distributors to continue to bring the product to the attention of new customers,
and (b) Registrant's success in bringing to market new forms of LUBRAJEL that
will enable the product to be used in new applications. Registrant is currently
developing new varieties of LUBRAJEL for this purpose, and is in the process of
introducing several new types of LUBRAJEL products under a "LUBRAJEL II"
designation, which it hopes will expand its market for this product line.
Registrant believes that there is still significant potential to expand the
sales of its LUBRAJEL line of products by (a) increasing the number of potential
products in which it can be used, and (b) by continuing to increase its
marketing efforts into new markets that have only been developed recently, such
as in China.
Registrant is also continuing to work with a global personal care products
company in the U.K. that is using LUBRAJEL FLUID, a modified form of LUBRAJEL,
as a condom lubricant. The initial expectations for this product have not been
realized due to the decreased urgency on the part of the customer to switch to
Registrant's product from the silicone-based product they are currently using.
However, the customer is continuing to expand its purchases, and Registrant
expects sales to gradually increase as it is incorporated further into their
product lines.
Registrant believes that any sales increases in the LUBRAJEL line of
products may be offset somewhat by continuing competition from products
introduced by Registrant's competitors. Despite this competition, Registrant
believes that it will still be able to expand the market for its LUBRAJEL
product line. Registrant believes that LUBRAJEL'S reputation for quality and
customer service will enable it to continue to compete effectively in the
marketplace.
RENACIDIN
RENACIDIN is a urological prescription drug, approved in the U.S. only,
which is used primarily to prevent the formation of and to dissolve
calcifications in catheters implanted in the urinary bladder. It is marketed as
a ready to use sterile solution under the name "RENACIDIN IRRIGATION". RENACIDIN
IRRIGATION is also approved for use in dissolving certain types of kidney
stones. On October 9, 1990, the Patent Office issued to the Registrant patent #
4,962,208, which expires on October 9, 2007, covering the method of
manufacturing RENACIDIN IRRIGATION. Sales of RENACIDIN IRRIGATION in 2003
accounted for 17% of Guardian's sales and 16% of the sales of the Registrant as
a whole. Sales of RENACIDIN IRRIGATION in 2003 increased 14% from $1,538,191 in
2002 to $1,748,106 in 2003. This increase was the result of a 9% increase in
unit sales as well as a price increase that went into effect on June 1, 2003,
which accounted for the remainder of the sales increase. In prior years, unit
sales have also been affected by the ordering patterns of drug wholesalers.
Other Products
Other significant products that are manufactured and sold by Guardian but
which did not individually comprise more than 5% of the Registrant's sales in
2003 are as follows:
CLORPACTIN(R) WCS-90 is a microbicidal product used primarily in urology
and surgery as an antiseptic for treating a wide range of localized infections
in the urinary bladder, the peritoneum, the abdominal cavity, the eye, ear, nose
and throat, and sinuses. The product is a white powder that is made into a
liquid prior to use. It is a powerful disinfectant, fungicide, deodorizer,
bleach, and detergent. Sales of CLORPACTIN were up 6% from $296,764 in 2002 to
$313,277 in 2003. This change was primarily the result of a price increase
implemented on June 1, 2003, as well as a slight increase in unit sales.
KLENSOFT(TM) is a surfactant (a surface active agent, such as a soap or
detergent, that can reduce the surface tension of a liquid and thus allow it to
foam or penetrate solids or act as a wetting agent), that can be used in
shampoos, body washes, makeup removers, and other cosmetic formulations. The
primary customer for Klensoft for many years has been in Taiwan, and over the
past few years there have been new customers for the product in the United
Kingdom, Australia, France and Korea. Klensoft sales in 2003 were $140,238,
virtually the same as the prior year sales level. Although Registrant has
thought that sales in 2003 would increase over 2002, the erratic purchasing
patterns of the major customer in Taiwan make it difficult to predict sales from
year to year.
LUBRAJEL PF is a preservative-free form of LUBRAJEL currently being
marketed primarily by Societe D'Etudes Dermatologiques ("Sederma") under the
tradename "Norgel". Sederma is the Registrant's distributor of LUBRAJEL in
France and a major European cosmetic ingredient supplier. It is also distributed
by some of Registrant's other marketing partners under the name LUBRAJEL PF.
Tests conducted by Sederma indicated that the product self-preserved, and aided
in the preservation of other cosmetic ingredients with which it was formulated.
Sales of Lubrajel PF increased 41% from $60,900 in 2002 to $85,699 in 2003.
(These sales are already included in the total Lubrajel sales figure mentioned
previously). This increase is primarily the result of purchasing patterns.
LUBRAJEL RR and RC are special grades of LUBRAJEL that can withstand
sterilization by gamma radiation, which is one of the methods of terminally
sterilizing medical and hospital products. On April 11, 1995, the Registrant was
granted a U.S. patent for this unique form of LUBRAJEL. In September, 1994 the
Registrant entered into a marketing agreement with Avail Medical (formerly
"Horizon Medical, Inc."), a California company engaged in the development and
manufacturing of products and services to the medical device and pharmaceutical
industries. Avail has been actively marketing LUBRAJEL RC since January, 1996.
Sales of LUBRAJEL RC increased by 37% from $318,636 in 2002 to $437,101 in 2003.
(These sales are already included in the total Lubrajel sales figure mentioned
previously). Sales to Avail have shown a steady increase over the past three
years.
CONFETTI(TM) II DERMAL DELIVERY FLAKES is a product line introduced in 2000
that incorporates various functional oil-soluble ingredients into colorful
flakes that can be added to, and suspended in, various water-based products. The
product color and ingredients can be customized to meet the needs of individual
customers. Sales of Confetti II increased from $34,952 in 2002 to $52,886 2003,
an increase of 51%.
Other products that do not have significant sales at the present time but
have the potential for increased sales in the future, and which as a group
constituted approximately 5% of Registrant's sales in 2003, are as follows:
LUBRASIL and LUBRASIL DS are special types of LUBRAJEL in which silicone
oil is incorporated into a LUBRAJEL base by microemulsification, while
maintaining much of the clarity of regular LUBRAJEL. The products have a silky
feel, and are water resistant while moisturizing the skin. (These sales are
already included in the total Lubrajel sales figure mentioned previously).
RAZORIDE(TM) is a clear, hypo-allergenic, non-foaming, water-based shaving
product that is surfactant and soap-free and has excellent lubricity and
moisturizing properties.
UNITWIX(R) is a cosmetic additive used as a thickener for oils and
oil-based liquids. It is a proprietary, unpatented product that does not require
government approval to market. A new form of Unitwix was introduced in fiscal
year 2000.
DESELEX(R) is a replacement for phosphates in detergents.
B-122(TM) and a related product, LUBRASLIDE(TM), are powdered lubricants
used in the manufacture of cosmetics such as pressed powders, eye liners, and
rouges. They are used as binders for these products, increasing their drop
strength and lowering the coefficient of friction and water-repellency.
HYDRAJEL PL and HYDRAJEL VM are personal lubricants and moisturizers
developed specifically for the feminine personal care market. Although sales
have not been significant to date, a number of companies are evaluating these
products for possible inclusion into their product lines.
ORCHID COMPLEX(TM) is a successor product to Registrant's previous Oil of
Orchids product and is a base for skin creams, lotions, cleansers, and other
cosmetics. This product is an extract of fresh orchids, modified by extractants,
stabilizers, and preservatives, and is characterized by its excellent lubricity,
spreadability and light emolliency. Because of its alcohol solubility, it may
also be used in fragrance products such as perfumes and toiletries. Its light
emolliency lends use in shampoos, bath products and facial cleansers. It is also
a superior emollient for sunscreens, vitamin creams, toners and skin serums. It
is sold in two forms, water-soluble and oil soluble.
Development Activities
Guardian's Research and Development Department has developed a large number
of products that can be used in many different industries, including the
pharmaceutical, medical, cosmetic, health care, and specialty chemical
industries. These products are in various stages of development, some being
currently marketable and some being in the very early stages of development
requiring a substantial amount of development work to bring them to market. New
uses for currently marketed products are also being developed. Once a product is
created, the initial development work on it may consist of one or more of the
following: (a) laboratory refinements and adjustments to suit the intended uses
of the product; (b) stability studies to determine the effective shelf-life of
the product and suitable storage and transportation conditions for the product;
and (c) laboratory efficacy tests to determine the effectiveness of the product
under different conditions.
After the Research and Development Department has completed its initial
work on a product and is satisfied with the results of that work, further
development work to bring the product to market will continue, including some or
all of the following: (a) animal and human clinical studies needed to determine
safety and effectiveness of drug or medical device products, which would be
needed for submissions to the appropriate regulatory agencies, such as the
United States Food and Drug Administration ("FDA") or the United States
Environmental Protection Agency ("EPA"); (b) preparatory work for the filing of
Investigational New Drug Applications or New Drug Applications; (c) market
research to determine the marketability of the product, including the potential
market size and most effective method of marketing the product; (d) scaling up
from laboratory production batches to pilot batches, and then to full scale
production batches, including the determination of the type of equipment
necessary to produce the product; (e) upgrading or purchasing new equipment to
manufacture the products; and (f) the negotiation of joint venture or
distribution agreements to develop and/or market the product. Some of the
foregoing work may be done by outside contractors.
While there can be no assurance that any particular project will result in
a new marketable product or a commercially successful product, the Registrant
believes that a number of its development projects, including those discussed
below, may have commercial potential.
LUBRAJEL
Registrant's major research focus at the present time is the development of
new and unique personal care ingredients. The following are some of the projects
the Registrant is working on at the present time:
"Lubrajel II": This is a new line of water-based gels that will be
supplements to, and not replacements for, the current Lubrajel line. The
products in this line will consist of a modified Lubrajel composition that
enhances some of the properties of the current Lubrajel line, and allows it to
be used as a drop-in replacement for one of Lubrajel's main competitors. Its
composition also will enable it to be used in certain countries, such as Japan,
more easily than the current Lubrajel formulation. The first product in this
line, "Lubrajel II XD", was introduced last spring, and while sales are still
small, they are gradually increasing. The second product in this line, "Lubrajel
II XL", will be a high lubrication gel. Registrant anticipates introducing this
product in the second quarter of 2004. In addition, a new preservative-free form
is also under development. Registrant believes that this new line will enable it
to recover some of the business it has lost to its competitors over the years,
and will give customers even greater formulating choices.
"PLEXAJEL(R)": This product, marketed by the Registrant under the name
"Plexajel ASC" (for "Acid Stable Complex") was introduced last year. Its
formulation was developed to allow customers to incorporate low pH ingredients,
such as alpha hydroxy acids, into clear, water-based gel formulations. Sales of
this new product were lower than expected because customers were finding that
too high a percentage of the product needed to be used in their formulations in
order to take full advantage of its properties. Registrant is currently working
with its marketing partners to reposition this product for better marketability,
and hopes to find new uses for it that were not originally envisioned.
CLORONINE
Cloronine is a powerful disinfectant, germicide, and sanitizer for
disinfecting medical and surgical instruments and equipment (particularly where
autoclaves are not available), and for the purification of water supplies. The
product had been approved for certain uses in France and Canada, and is still
being sold in Canada. Registrant is currently working with a new potential
customer for this product; however, before this product can be marketed in the
United States for any purpose, additional tests will have to be done to
determine if the product can be registered with the EPA as a sterilant or
germicide. These tests would comprise laboratory microbiological studies,
compatibility studies, and specific studies on its intended uses. The product
will also have to be registered with the FDA as an accessory to a medical
device. Neither registration process has yet begun. Due to the expense and time
required, the Registrant hopes to work jointly with other companies to obtain
these registrations. The Registrant was granted two patents for this product.
CLORPACTIN
In 2002 the Registrant completed a small preliminary clinical trial in
conjunction with the School of Dental Medicine at Boston University to determine
whether Clorpactin, Registrant's proprietary antimicrobial product, would be
effective in the treatment of gingivitis and other periodontal disease. The
results of that initial test were very positive, but indicated that it would be
necessary to alter the taste of the product in order to achieve the proper
patient compliance. As a result, the Registrant is conducting an additional
larger study with Boston University using a modified form of Clorpactin that
Registrant hopes will solve that problem. The study is ongoing at the present
time, and interim results have been mixed, with many participants still not
satisfied with the taste. After all the results are in, Registrant will make a
determination as to whether it can resolve the outstanding issues sufficiently
to justify continuing with the project. If it is decided to continue the
project, Registrant intends to endeavor to locate a partner to work with it to
obtain the regulatory approvals that will be needed in order to market the
product for this new use.
Trademarks and Patents
The Registrant strongly believes in protecting its intellectual property
and intends whenever possible to make efforts to obtain patents in connection
with its product development program. The Registrant currently owns many United
States patents and trademarks relating to its products. The Registrant has
patent and trademark applications pending with respect to a number of its
research and development products. Patents formerly held by the Registrant on
certain products have expired. There can be no assurance that any patents held
by the Registrant will be valid or otherwise of value to the Registrant or that
any patent applied for will be granted. However, the Registrant believes that
its proprietary manufacturing techniques and procedures with respect to certain
products offer it some protection from duplication by competitors regardless of
the patent status of the products.
The various trademarks and trade names owned or used by the Registrant in
Guardian's business are of varying importance to the Registrant. The most
significant products for which the Registrant has a registered trademark are
LUBRAJEL, RENACIDIN, and CLORPACTIN.
Set forth below is a table listing certain information with respect to all
unexpired U.S. patents held by the Registrant:
PATENT NAME PATENT # ISSUE DATE EXPIRATION
DATE
------------------------------------------------ --------- ---------- ----------
Treatment of Hazardous Waste - ternary alloy and oil 4,695,400 9/22/87 9/22/04
slurry thereof; sodium, copper, lead
Iodophor; Polyethylene Glycol Alkylaryl-sulfonate 4,873,354 10/10/89 10/10/06
Iodine complex
Thermal Resistant Microbial Agent ("Cloronine") 4,954,316 9/4/90 9/4/07
Method of Preparing Time-Stable Solutions of Non- 4,962,208 10/9/90 10/9/07
Pyrogenic Magnesium Gluconocitrate ("Renacidin
Irrigation")
Use of Clorpactin for the Treatment of Animal 4,983,634 1/8/91 1/8/08
Mastitis & the applicator used in that treatment
(owned jointly by the Registrant and Diversey Ltd.)
Iodophor; biocide; reacting polyethylene glycol, 5,013,859 5/7/91 5/7/08
alkylarylsulfonate and Iodine water-propylene glycol
solvent refluxing
Stabilized Beta Carotene 5,023,355 6/11/91 6/11/08
Stable, Active Chlorine Containing Anti-microbial 5,128,342 7/7/92 7/7/09
Compositions ("Cloronine")
Gamma Radiation Resistant Lubricating Gel 5,405,622 4/11/95 4/11/12
Delivery system for oil soluble actives in cosmetic/ 6,117,419 9/12/00 9/12/17
personal care products
Microemulsion of silicone in a water-based gel that 6,348,199 2/19/02 2/19/19
forms a clear, transparent, highly stable moisturizer
and lubricant for cosmetic and medical use
The Registrant requires all employees and consultants who may receive
proprietary information to agree in writing to keep such proprietary information
confidential.
Eastern Chemical Corporation
Eastern is a wholly owned subsidiary of the Registrant. It distributes an
extensive line of fine organic chemicals, research chemicals, test solutions,
indicators, dyes and stains, and reagents. In 2003, Eastern's sales accounted
for approximately 10% of the total product sales of the Registrant versus 13% in
2002. Eastern's sales decreased by 6% in 2003. The decrease was partially the
result of a loss of sales due to Registrant's continuing efforts to reduce
Eastern's inventory, which resulted in an inability to supply certain items that
required immediate shipment from inventory, and partly the result of a general
decrease in Eastern's business due to competition from new companies in this
field. Registrant believes that much of the impact from the reduction in
Eastern's inventory has already been absorbed over the past three years.
Marketing
Guardian markets its products through (a) distributors; (b) advertising in
medical and trade journals, by mailings to physicians and to the trade; and (c)
exhibitions at appropriate medical meetings. The pharmaceutical products are
sold in the United States primarily to drug wholesalers that distribute to drug
stores for resale, and to hospitals, physicians, the Veteran's Administration,
and other government agencies. The proprietary personal care and specialty
chemical products are sold to distributors for resale and directly to
manufacturers for use as ingredients or additives in the manufacture or
compounding of their cosmetic, personal care, or chemical products.
Eastern's products are marketed through advertising in trade publications
and direct mailings. They are sold to distributors and directly to users in a
wide variety of applications. Eastern does not sell any unique products and is
not dependent on any single customer or group of customers on a continuous
basis.
Domestic Sales
In the United States Registrant's cosmetic products are marketed
exclusively by International Specialty Products ("ISP") in accordance with a
marketing agreement entered into in 1996 and subsequently amended and expanded
in 2000, and 2002 (see "Marketing Agreements" below). ISP also has certain
rights to sell some of Registrant's other industrial and medical products. In
2003, ISP's purchases for distribution in the United States were estimated to be
approximately $1,667,254 compared to $837,218 in 2002, an increase of 99%, and
accounted for approximately 15% of the Registrant's sales (an estimate based on
sales information provided to Registrant by ISP.
Registrant has no way of independently determining which of ISP's purchases from
Registrant are intended for domestic sale and which are intended for foreign
sale.) Registrant believes that the increase in ISP's domestic sales of
Registrant's products was due new product launches as well as increased overall
demand for Registrant's product in the U.S.
Registrant's domestic sales of pharmaceutical products are handled
primarily through the major full-line drug wholesalers and account for
approximately 18% of Registrant's sales. Registrant's other products, such as
its industrial products, are sold directly to end-users and account for less
than 2% of sales
Foreign Sales
In 2003 and 2002 Registrant derived approximately 49% of its sales from
customers in foreign countries, primarily from sales of its cosmetic products in
Europe and Asia. The Registrant currently has 6 distributors for its cosmetic
products outside the United States: S. Black Ltd. in the United Kingdom ("S.
Black"); Sederma in France; Luigi & Felice Castelli S.R.L. in Italy; S. Black
Gmbh in Switzerland; C&M International in Korea; and ISP in Germany, Spain,
Scandinavia, Eastern Europe, the Benelux countries, Canada, Mexico, South &
Central America, Asia (with the exception of Korea), and most of the remaining
foreign markets. Registrant's foreign sales attributable to each of its foreign
distributors as a percentage of Registrant's total foreign sales were as
follows: ISP: 50% (an estimate of ISP's purchases intended for sale outside the
U.S., based on foreign sales figures provided to the Registrant by ISP);
Sederma: 20%; S. Black: 9%; C&M International: 8%; and Castelli: 2%.
Marketing Agreements
ISP
In December, 2002 Registrant entered into a new marketing agreement with
ISP, which modified and consolidated three previous marketing agreements entered
into with ISP in 1994, 1996, and 2000. The previous agreements had granted ISP
the right to market Registrant's personal care products, as well as some medical
and industrial products, in the United States, Canada, Mexico, Central and South
America, Europe (excluding France, Italy, and Switzerland), Asia (except Korea),
Australia, and Africa. The 2000 agreement gave Registrant greater flexibility in
appointing other marketing partners in areas where ISP is not active or has not
been successful, and gave ISP certain additional territories in which they can
market the Registrant's products. The agreement provided for exclusivity for ISP
in those markets as long as annual minimum purchase requirements were met. The
2002 agreement provided for automatic extensions of the agreement through
December, 2008 provided ISP meets certain purchase requirements during each year
of the agreement. ISP manufactures and markets an extensive line of personal
care, pharmaceutical, and industrial products on a global basis.
Registrant believes that in the event ISP were to cease marketing
Registrant's products, alternative arrangements could be made to continue to
supply product to the customers currently using Registrant's products without
any significant interruption of supply.
Registrant has other marketing arrangements with marketing partners in the
U.K, France, Switzerland, Korea, and Italy, but all of these other arrangements
are operating under either verbal agreements or expired written agreements, and
are subject to termination at any time by either party.
Raw Materials
The principal raw materials used by the Registrant consist of common
industrial organic chemicals, laboratory reagents, and common inorganic
chemicals. Most of these materials are available in ample supply from numerous
sources. The Registrant's principal raw material suppliers are Proctor and
Gamble, Callahan Chemical Company, Univar USA, Inc., Protameen Chemicals Inc.,
Alzo, Inc., Esprit Chemical Company LP, Eastman Chemical Products, Clariant
Corp., Ishihara U.S.A., Nissei Trading Co., Varessa, Ltd., E.I. duPont, S.A.
Fine Chemicals, and Loba Chemie.
Inventories; Returns and Allowances
The Registrant's business requires that it maintain moderate inventories of
certain of its finished goods. Historically, returns and allowances have not
been a significant factor in the Registrant's business.
Backlog
The Registrant currently does not have any significant backlog.
Competition
Guardian has many products or processes that are either unique in their
field or have some unique characteristics, and therefore are not in direct
competition with the products or processes of other pharmaceutical, personal
care, chemical, or health care companies. However, the pharmaceutical, health
care, and cosmetic industries are all highly competitive, and the Registrant
expects competition to intensify as advances in the field are made and become
widely known. There may be many domestic and foreign companies that are engaged
in the same or similar areas of research as those in which the Registrant is
engaged, many of which have substantially greater financial, research, manpower,
marketing and distribution resources than the Registrant. In addition, there are
many large, integrated and established pharmaceutical, chemical and cosmetic
companies that have greater capacity than the Registrant to develop and to
commercialize types of products upon which the Registrant's research and
development programs are based. However, Registrant believes that the expense of
testing and evaluating possible substitutes for Registrant's products that are
already in customers' formulations, as well as the expense to the customer in
relabeling its products, is a significant barrier to displacing Registrant's
products in current customer formulations. These cost factors make it less
likely that a customer would choose a competitive product unless there was a
significant cost savings in doing so. The Registrant believes that
manufacturing, regulatory, distribution and marketing expertise will be
increasingly important competitive factors in favor of the Registrant. In this
regard, the Registrant believes that arrangements with major health care and
medical or hospital products suppliers will be important factors in the
commercialization of many of the products which it is currently developing.
Eastern faces competition from many other chemical manufacturers and
distributors, many of which have much greater financial resources than those of
the Registrant. Eastern's competition is based primarily upon price, service and
quality. Eastern attempts to maintain its competitive position in the industry
through its ability to (i) locate and make wholesale arrangements to purchase
the chemicals with suppliers located all over the world, (ii) maintain a
sufficient inventory of its most popular items at all times, and (iii) customize
each order as to quantity of the item requested and to tailor the price of the
order to such quantity. Eastern's primary competitors are SA Fine Chemicals,
Acros Organics, Pfaltz & Bauer, Inc., and Spectrum Chemical Mfg. Corp.
ISO-9001:2000 REGISTRATION
In December, 2003 Registrant earned ISO 9001:2000 registration from
Underwriters Laboratories, Inc., indicating that the Registrant's documented
procedures and overall operations had attained the high level of quality needed
to comply with this new ISO certification level. Prior to that, in November,
1998 the Registrant had earned ISO-9002 registration, and had been in continual
compliance with that standard since that time. Registrant will continue to be
evaluated every six months for continued compliance with the new ISO-9001:2000
standard, and is currently in good standing under this new registration.
Government Regulation
Regulation by governmental authorities in the United States and other
countries is a significant factor in the manufacturing and marketing of many of
the Registrant's products. The Registrant and many of Registrant's products are
subject to certain government regulations. Products that may be developed and
sold by the Registrant in the United States may require approval from federal
regulatory agencies, such as the FDA, as well as state regulatory agencies.
Products that may be developed and sold by the Registrant outside of the United
States may require approval from foreign regulatory agencies. Any medical device
products developed by the Registrant will be subject to regulation by the Center
for Devices and Radiological Health of the FDA, and will usually require a
510(k) pre-market notification. Most pharmaceutical products will require
clinical evaluation under an Investigational New Drug ("IND") application prior
to submission of a New Drug Application ("NDA") for approval of a new drug
product.
A drug product normally must go through several phases in order to obtain
FDA approval. The research phase involves work up to and including discovery,
research, and initial production. Next is the pre-clinical phase, which involves
studies in animal models necessary to support an IND application to the FDA and
foreign health registration authorities to commence clinical testing in humans.
Clinical trials for pharmaceutical products are conducted in three phases. In
Phase I, studies are conducted to determine safety and dosages. In Phase II,
studies are conducted to gain preliminary evidence as to the efficacy of the
product. In Phase III, studies are conducted to provide sufficient data for the
statistical proof of safety and efficacy, including dose regimen. Phase III is
the final stage of such clinical studies prior to the submission of an
application for approval of an NDA. The amount of time necessary to complete any
of these phases cannot be predicted with any certainty.
In all cases, the Registrant is required to comply with all pertinent Good
Manufacturing Practices of the FDA for medical devices and drugs. Accordingly,
the regulations to which the Registrant and certain of its products may be
subject, and any changes with respect thereto, may materially affect the
Registrant's ability to produce and market new products developed by the
Registrant.
The Registrant's present and future activities are, and will likely
continue to be, subject to varying degrees of additional regulation under the
Occupational Safety and Health Act, Environmental Protection Act, import, export
and customs regulations, and other present and possible future foreign, federal,
state and local regulations.
Portions of the Registrant's operating expenses are directly attributable
to complying with federal, state, and local environmental statutes and
regulations. In 2003 and 2002 the Registrant incurred approximately $47,000 and
$43,000 respectively, in environmental compliance costs.
Research and Development Expense
Portions of the Registrant's operating expenses are directly attributable
to research and development the Registrant performs. In 2003 and 2002, the
Registrant incurred approximately $403,000 and $348,000, respectively, in
research and development expenses. No portion of the research and development
expenses was directly paid by the Registrant's customers.
Employees
The Registrant presently employs 43 people, 7 of whom serve in an executive
capacity, 21 in research, quality control and manufacturing, 5 in maintenance
and construction, and 10 in office and administrative work. Of the total number
of employees, 41 are full time employees. None of the Registrant's employees are
covered by a collective bargaining agreement. The Registrant believes that its
relations with its employees are satisfactory.
Item 2. Description of Property.
The Registrant maintains its principal office, factory, and conducts most
of its research at 230 Marcus Boulevard, Hauppauge, New York 11788. These
premises, which the Registrant owns, contain approximately 30,000 square feet of
manufacturing space, 15,000 square feet of warehouse space, and 5,000 square
feet of office and laboratory space on approximately 2.7 acres of land. The
Registrant has now fully developed the 2.7 acres, and fully utilizes the
buildings occupying the land. The Registrant believes that the aforementioned
property is adequate for its immediately foreseeable needs. The property is
presently unencumbered and is adequately insured.
Item 3. Legal Proceedings
In September, 2003 the Company was served with a complaint and proposed
order by the U.S. Environmental Protection Agency ("EPA") alleging that (a) the
Company had failed to perform certain testing of its pharmaceutical waste water
prior to having it disposed of by the licensed contractor it had been using for
many years, and (b) that it had failed to provide the proper paperwork regarding
such testing. Because the pharmaceutical waste generated by the Company is so
small (averaging only about 1% of its annual waste water) it was not aware that
it was subject to these requirements. The Company met with the EPA, which
accepted the Company's explanation that its failure to comply was inadvertent,
and entered into a consent decree that neither admitted nor denied any liability
but provided for a civil penalty of $23,000, which the Company paid. The EPA has
agreed that as long as the Company files the required reports that it will not
pursue any further action and the matter will be closed.
Item 4. Submission of Matters to a Vote of Security Holders.
None.
PART II
Item 5. Market for Common Equity and Related Stockholder Matters.
Market Information
The Common Stock of the Registrant is traded on the American Stock Exchange
(the "AMEX") under the symbol "UG". The following table sets forth for the
periods indicated the high and low closing sale prices of the shares of Common
Stock, as reported by the AMEX Market Statistics for the period January 1, 2002
to December 31, 2003. The quotations represent prices between dealers and do not
include retail markup, markdown or commission:
Year Ended Year Ended
Quarters December 31, 2003 December 31, 2002
-------- ----------------- -----------------
High Low High Low
---- --- ---- ---
First (1/1 - 3/31) $ 4.63 4.00 $ 6.36 $ 5.10
Second (4/1 - 6/30) $ 8.60 4.29 $ 7.36 $ 5.20
Third (7/1 - 9/30) $ 8.55 6.95 $ 5.45 $ 3.74
Fourth (10/1 - 12/31) $ 8.90 7.35 $ 4.20 $ 3.25
Holders of Record
As of March 1, 2004 there were 1297 holders of record of Common Stock.
Cash Dividends
On January 5, 2004 the Registrant paid a $.15 per share dividend to all
stockholders of record as of December 15, 2003. On January 8, 2003 the
Registrant paid a $.10 per share dividend to all stockholders of record as of
December 20, 2002.
Item 6. Management's Discussion and Analysis or Plan of Operation
Results Of Operations:
Year Ended December 31, 2003 Compared to
Year Ended December 31, 2002
Revenue
Consolidated revenue in 2003 increased by $2,066,007 (23%) compared to 2002
due to a revenue increase in the Guardian Division of $2,130,549 (27%) partially
offset by a decrease in revenues in the Eastern Division of $64,542 (6%).
The increase in Guardian's sales is due to an overall increase in demand
for Guardian's products. Some of this demand may be attributable to new launches
of personal care products that contain ingredients produced by Guardian, by
companies that had been refraining from launching new products due to the poor
economic conditions that have prevailed in both the U.S. and overseas. Based on
information provided to the Company by its distributors, over the past year or
so there has been an increase in activity on the part of many customers, which
has resulted in increased demand for the Guardian's products.
The decline in Eastern's sales was partially the result of a loss of sales
due to the Company's continuing efforts to reduce Eastern's inventory, which
resulted in an inability to supply certain items that required immediate
shipment from inventory. Also contributing to the decline was a general decrease
in Eastern's business due to competition from new companies in this field. The
Company does not anticipate any significant increase or decrease in Eastern's
sales in the near future.
Cost of Sales
Cost of sales as a percentage of sales in 2003 decreased to 45.4% from
53.9% in the prior year. This decrease is mainly due to (a) increased sales
resulting in increased manufacturing, which reduced the per unit overhead cost,
resulting in a favorable production variance, and (b) savings in disposal costs
and obsolete inventory of approximately $60,000 and $147,000 in 2003 and 2003
respectively. The Company had recorded such reserves in prior years. Excluding
the savings from the disposal and obsolete inventory, cost of sales as a
percentage of sales, would have been 47.3%.
Operating Expenses
Operating expenses increased by $152,210 (7%) compared to the prior year.
The increase is due to increases in Director fees, insurance costs, payroll
related costs, bad debt write offs, research and development, advertising costs
and the payment of a civil fine (see "Legal Proceedings"). These increases were
partially offset by decreases in depreciation and amortization expenses, legal
expenses and office expenses.
Other Income (Expense)
Investment income decreased to $168,867 in 2003 from $192,132 in 2002. This
12% decrease is attributable to a decline in interest rates.
Provision for Income Taxes
The provision for income taxes increased to $1,339,757 in 2003 from
$662,341 in 2002. The increase was due to an increase in income before taxes of
$1,727,065 (83%) for the year ended December 31, 2003.
Liquidity and Capital Resources
Working capital increased to $11,599,502 at December 31, 2003 from
$9,578,365 at December 31, 2002, an increase of $2,021,137 (21%). The current
ratio decreased to 9.3 to 1 at December 31, 2003 from 10.4 to 1 at December 31,
2002. The decrease in current ratio was due primarily to an increase to $.15 per
share for the dividends declared in 2003 and paid in 2004 as compared to $.10
per share that was declared in 2002 and paid in 2003.
The Company has a line of credit agreement with a bank for borrowings of up
to $700,000, which expires in May, 2004 and which the Company plans to renew. As
of December 31, 2003, there were no outstanding borrowings on this line of
credit.
The Company generated cash from operations of $2,631,957 in 2003 compared
to $1,944,067 in 2002. The increase in 2003 was primarily due to the increase in
net income. During 2003 and 2002 the Company invested approximately $118,179 and
$131,650, respectively, in plant and equipment. Cash used in investing
activities was $2,764,260 for the year ended December 31, 2003, whereas cash
provided by investing activities was $91,744 for the year ended December 31,
2002. The decrease of $2,856,004 was mainly due to the purchase of marketable
securities (primarily bonds) and the redemption of some certificates of deposit.
Cash used in financing activities was $342,267 and $451,069 during the years
ended December 31, 2003 and 2002, respectively. The decrease was primarily due
to an increase in proceeds from stock options exercised during 2003. The Company
believes that its working capital is sufficient to support its operating
requirements for the next fiscal year. The Company's long-term liquidity
position will be dependent upon its ability to generate sufficient cash flow
from profitable operations. The Company has no material commitments for future
capital expenditures.
Commitments
The Company currently does not have any significant commitments.
Impact of Inflation, Changing Prices, and Seasonality
While it is difficult to assess the impact of inflation on the Company's
operations, management believes that, because of the proprietary nature of the
majority of its product line, inflation has had little impact on net sales.
Sales have changed as a result of volume and product mix. While inflation has
had an impact on the cost of sales and payroll, these increases have been
recaptured by price increases to the greatest extent possible. The Company's
products and sales are not considered to be seasonal, and are generally
distributed evenly throughout the year.
Critical Accounting Policies
The Company's financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America. As
such, some accounting policies have a significant impact on amounts reported in
the financial statements. A summary of those significant accounting policies can
be found in Notes to Financial Statements: Note A - Nature of Business and
Summary of Significant Accounting Policies. In particular, judgment is used in
areas such as determining the allowance for doubtful accounts, adjustments to
inventory valuations, and asset impairments.
Item 7. Financial Statements.
Annexed hereto starting on page F-1
Item 8. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
Not Required.
Item 8A. Controls and Procedures
As of March 1, 2004, an evaluation was performed by the Registrant's Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of the Registrant's disclosure controls and procedures.
Based on that evaluation, the Registrant's Chief Executive Officer and Chief
Financial Officer concluded that the Registrant's disclosure controls and
procedures are effective in ensuring that material information related to the
Registrant is made known to them by others within the Registrant. There have
been no significant changes in the Registrant's internal controls or in other
factors that could significantly affect internal controls subsequent to March 1,
2004.
PART III
Item 9. Directors, Executive Officers, Promoters and Control Persons;
Compliance With Section 16(a) of the Exchange Act.
Directors and Executive Officers
Set forth in the table below is certain information as of March 1, 2004
with respect to the executive officers and directors of the Registrant:
Name Age Position(s) with the Registrant
---------------------- ----- ----------------------------------
Dr. Alfred R. Globus 83 Chairman of the Board, Chief
Executive Officer and Director
Kenneth H. Globus 52 President, Chief Financial Officer,
General Counsel and Director
Robert S. Rubinger 61 Executive Vice President,
Secretary, Treasurer and Director
Charles W. Castanza 71 Senior Vice President and Director
Derek Hampson 64 Vice President
Joseph J. Vernice 45 Vice President
Peter A. Hiltunen 45 Vice President
Lawrence F. Maietta 46 Director
Henry P. Globus 81 Director
Benjamin Wm. Mehlman 93 Director
Arthur M. Dresner 62 Director
Andrew A. Boccone 58 Director
Dr. Alfred Globus has been Chairman of the Board and Chief Executive
Officer of the Registrant since July, 1988. He served as Chairman of the Board
and President of the Registrant from the inception of the Registrant in 1942
until July, 1988. He has been a director of the Registrant since 1942.
Kenneth H. Globus has been President and General Counsel of the Registrant
since July, 1988. He served as Vice President and General Counsel of the
Registrant from July, 1983 until July, 1988. He has been a director of the
Registrant since 1984. He became the Chief Financial Officer in November, 1997.
Robert S. Rubinger has been Executive Vice President and Secretary of the
Registrant since July, 1988, and Treasurer since May, 1994. He served as Vice
President and Secretary of the Registrant from February, 1982 until July, 1988.
He has been a director of the Registrant since 1982.
Charles W. Castanza has been a Senior Vice President of the Registrant
since March 2000. He served as Vice President from April, 1986 until March 2000.
He served as Operations Manager of Chemicals and Pharmaceuticals of the
Registrant from February, 1982 until April, 1986. He has been a director of the
Registrant since 1982.
Derek Hampson has been a Vice President of the Registrant since October,
1987. He has served as Manager of the Eastern Chemical Corp. subsidiary since
1971.
Joseph J. Vernice has been a Vice President of the Registrant since
February, 1995. He served as Assistant Vice President of the Registrant from
November, 1991 until February, 1995. He has been Manager of Research and
Development for the Registrant since 1988 and Director of Technical Services
since 1991.
Peter A. Hiltunen has been a Vice President of the Registrant since July,
2002. He served as Assistant Vice President of the Registrant from November,
1991 until July, 2002. He has been Production Manager of the Registrant since
1982.
Lawrence F. Maietta has been a partner in the public accounting firm of
Bonamassa, Maietta & Cartelli, LLP in Brooklyn, NY since October, 1991. For more
than five years prior to that he was a partner in the public accounting firm of
Wilfred, Wyler & Co. in New York, NY. He was controller for the Registrant from
October, 1991 until November, 1997, and a director of the Registrant since
February, 1994.
Henry P. Globus has been a consultant to the Registrant since July, 1988.
He served as Executive Vice President of the Registrant from 1982 until July,
1988. He has been a director of the Registrant since 1947.
Benjamin William Mehlman was formerly a judge and attorney in private
practice until he retired from the practice of law in June, 1997. From 1984 to
1997 he had been counsel to the law firm of William T. Friedman and its
predecessor, Friedman and Shaftan. He has been a director of the Registrant
since 1964.
Arthur M. Dresner has been a partner in the law firm Reed Smith, LLP since
January, 2003. From 1998 to 2003 he had been "Of Counsel" to that firm as well
as to the law firm of McAulay, Nissen, Goldberg & Kiel LLP, which combined with
Reed Smith in 2000. From 1974 until 1997 he was employed as a Vice President in
corporate development and general management of International Specialty
Products, Inc., our major marketing partner. He has been a director of the
Registrant since April, 1997.
Andrew A. Boccone is an independent business consultant. From 1990 to his
retirement in 2001 he was President of Kline & Company, a leading international
business consulting and research firm that he first joined in 1974, developing
growth strategies and providing business solutions for many multinational
chemical companies. Prior to joining Kline & Company Mr. Boccone served in
various management positions at American Cyanamid. He has been a Director of the
Registrant since November, 2002.
Dr. Alfred R. Globus and Henry P. Globus are brothers. Kenneth H. Globus is
the son of Henry P. Globus and the nephew of Dr. Alfred R. Globus. There are no
other family relationships between any directors or officers of the Registrant.
The directors are elected to serve for one year or until the next Annual
Meeting of Stockholders and until their successors have been elected and
qualified.
Audit Committee Members and Financial Expert
The Board of Directors has an Audit Committee that meets with the Company's
independent auditors to review the plan, scope and results of its audits.
Members of the Audit Committee are Messrs. Benjamin Wm. Mehlman, Arthur Dresner,
and Andrew A. Boccone.
The Company does not have a "financial expert" (as that term is defined by
SEC regulations) on its audit committee due the expense involved in placing
another independent director on its Board of Directors and audit committee who
would qualify as such. Instead, the Company has asked one of its Board members,
Lawrence F. Maietta, a Certified Public Accountant, to act as an expert
financial advisor to the audit committee.
Code of Conduct and Ethics
The Company has adopted a Code of Conduct and Ethics that applies to all
officers, directors, and employees, serving in any capacity to the Company,
including the Chief Executive Officer, Chief Financial Officer, and principal
accounting Officer. A copy of the Company's Code of Conduct and Ethics is
available on the Company's web site at http://www.u-g.com. The Company intends
to satisfy the disclosure requirement under Item 10 of Form 8-K relating to
amendments to or waivers from any provision of our Code of Conduct and Ethics
applicable to Chief Executive Officer, Chief Financial Officer and principal
accounting officer by posting this information on our web site.
Compliance with Section 16(a) of the Exchange Act
The information required by this section is incorporated herein by
reference to the section entitled "Directors and Executive Officers - Section
16(a) Beneficial Ownership Reporting Compliance" of the proxy statement for the
2004 annual meeting of stockholders ("2004 Proxy Statement").
Item 10. Executive Compensation.
The information required by this Item is incorporated herein by reference
to the section entitled "Compensation of Directors and Executive Officers -
Summary Compensation Table" of the Company's definitive proxy statement which
will be filed no later than 120 days after December 31, 2003 ("2004 Proxy
Statement").
Item 11. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters.
The information required by this Item is incorporated herein by reference
to the sections entitled "Voting Securities and Principal Stockholders -
Security Ownership of Management" and "Compensation of Directors and Executive
Officers" of the 2004 Proxy Statement.
Item 12. Certain Relationships and Related Transactions.
Information required to be set forth hereunder has been omitted and will be
incorporated by reference, when filed, from the Company's 2004 Proxy Statement.
Item 13. Exhibits, List and Reports on Form 8-K
(a) Exhibits
3(a) Certificate of Incorporation of the Registrant as filed
April 22, 1987. Incorporated by reference to Exhibit 4.1 to
the Registrant's Current Report on Form 8-K, dated
September 21, 1987 (the "1987 8-K").
3(b) Certificate of Merger of United-Guardian, Inc. (New York)
with and into the Registrant as filed with the Secretary of
State of the State of Delaware on September 10, 1987.
Incorporated by reference to Exhibit 3(b) to the
Registrant's Annual Report on Form 10-K for the fiscal year
ended February 29, 1988 (the "1988 10-K").
3(c) By-laws of the Registrant. Incorporated by reference to
Exhibit 4.2 to the 1987 8-K.
4(a) Specimen Certificate for shares of common stock of the
Registrant. Incorporated by reference to Exhibit 4(a) to
the 1988 10-K.
10(a) Qualified Retirement Income Plan for Employees of the
Registrant, as restated April 1, 1976. Incorporated by
reference to Exhibit 11(c) of the Registrant's Registration
Statement on Form S-1 (Registration No. 2-63114) declared
effective February 9, 1979.
10(b) Employment Termination Agreement dated July 8, 1988 between
the Registrant and Henry Globus. Incorporated by reference
to Exhibit 10(i) to the Registrant's Annual Report on Form
10-K for the 10-month transition period from March 1, 1991
to December 31, 1991.
10(c) Exclusive Distributor Agreement between the Registrant and
ISP Technologies Inc., dated July 5, 2000. Incorporated by
reference to Exhibit 10(d) to the Registrant's Annual
Report on Form 10-KSB for the fiscal year ended December
31, 2000.
10(d) Letter Amendment between the Registrant and ISP
Technologies Inc. dated December 16, 2002 amending the
Exclusive Distributor Agreement between the Registrant and
ISP Technologies Inc. dated July 5, 2000. Incorporated by
reference to Exhibit 10(d) of Registrant's Annual Report on
Form 10-KSB for the fiscal year ended December 31, 2003.
21 Subsidiaries of the Registrant:
Jurisdiction of Name Under Which
Name Incorporation it does Business
Eastern Chemical Corporation New York (same)
Dieselite Corporation ** Delaware N/A
Paragon Organic Chemicals, Inc. New York (same)
Transcontinental Processes (Pty.) Ltd.* Australia N/A
* Inactive without assets
** Inactive
31.1 Certification of Alfred R. Globus, Chairman and Chief
Executive Officer of the Company, pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
31.2 Certification of Kenneth H. Globus, President and Chief
Financial of the Company, pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
32.1 Certification of Alfred R. Globus, Chairman and Chief
Executive Officer of the Company, pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
32.2 Certification of Kenneth H. Globus, President and Chief
Financial Officer of the Company, pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
(b) Reports on Form 8-K:
On May 8, 2003, August 5, 2003, and November 6, 2003, the Registrant filed
reports on Form 8-K disclosing the issuance press releases reporting the
quarterly earnings of the Company for the first, second, and third quarters of
2003 respectively. On December 5, 2003 the Registrant filed a report on Form 8-K
disclosing the issuance of a press release that announced the payment of a cash
dividend.
Item 14. Principal Accountant Fees and Services
Audit Fees
The aggregate fees billed by Eisner LLP for the audit of the Company's
annual financial statements and the reviews of the financial statements included
in the Company's quarterly reports on Form 10-QSB for FY-2003 were approximately
$49,000, including out of pocket expenses. In November, 2002 the Company changed
its principal accounting firm to Eisner LLP from Grant Thornton. The aggregate
fees billed by Grant Thornton for the reviews of the financial statements
included in the Company's quarterly reports on Form 10-QSB for FY-2002 were
estimated to be approximately $12,000. (The actual fee paid to Grant Thornton in
2002 was an annual fee; as a result, the Company has used Eisner LLP's fee to
estimate the amount of Grant Thornton's fee that would have related to the three
quarterly reports). The aggregate fees billed by Eisner LLP for the audit of the
Company's annual financial statements for FY-2002 were approximately $35,417.
Audit-Related Fees
There were no other fees billed by Eisner LLP or Grant Thornton during the
last two fiscal years that were reasonably related to the performance of the
audit or review of the Company's financial statements and not reported under
"Audit Fees" above.
Tax Fees
There were no other fees billed by Eisner LLP or Grant Thornton during the
last two fiscal years that related to tax preparation or compliance that were
not reported under "Audit Fees" above.
All Other Fees
There were no other fees billed by Eisner LLP or Grant Thornton during the
last two fiscal years for other products and services provided by Eisner LLP or
Grant Thornton.
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
UNITED-GUARDIAN, INC.
Dated: March 23, 2004 By: /s/ Alfred R. Globus
------------------------
Alfred R. Globus
Chief Executive Officer & Director
In accordance with the Exchange Act, this report has been signed
below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.
Signature Title Date
----------------------- --------------------------------- ---------------
By:/s/ Alfred R. Globus Chief Executive Officer, Director March 23, 2004
------------------------ (Principal Executive Officer)
Alfred R. Globus
By:/s/ Kenneth H. Globus President, General Counsel, March 23, 2004
------------------------ Director, Chief Financial
Kenneth H. Globus Officer(Principal Financial
and Accounting Officer)
By:/s/ Robert S. Rubinger Executive Vice President, March 23, 2004
------------------------ Secretary, Treasurer, Director
Robert S. Rubinger
By:/s/ Charles W. Castanza Senior Vice President, Director March 23, 2004
------------------------
Charles W. Castanza
By:/s/ Henry P. Globus Director March 23, 2004
------------------------
Henry P. Globus
By:/s/ Benjamin Wm. Mehlman Director March 23, 2004
------------------------
Benjamin Wm. Mehlman
By:/s/ Lawrence F. Maietta Director March 23, 2004
------------------------
Lawrence F. Maietta
By:/s/ Arthur M. Dresner Director March 23, 2004
------------------------
Arthur M. Dresner
By: /s/ Andrew A. Boccone Director March 23, 2004
------------------------
Andrew A. Boccone
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
----------
Independent Auditors' Report F-2
Financial Statements
Consolidated Balance Sheets as of December 31,
2003 and 2002 F-3 - F-4
Consolidated Statements of Income for the Years
Ended December 31, 2003 and 2002 F-5
Consolidated Statement of Stockholders' Equity
and Comprehensive Income for the Years Ended
December 31, 2003 and 2002 F-6
Consolidated Statements of Cash Flows for the
Years Ended December 31, 2003 and 2002 F-7
Notes to Consolidated Financial Statements F-8 - F-24
F-1
INDEPENDENT AUDITORS' REPORT
Board of Directors and Stockholders
United-Guardian, Inc.
Hauppauge, New York
We have audited the accompanying consolidated balance sheets of
United-Guardian, Inc. and subsidiaries as of December 31, 2003 and 2002 and the
related consolidated statements of income, changes in stockholders' equity and
cash flows for the years ended December 31, 2003 and 2002. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of
United-Guardian, Inc. and subsidiaries as of December 31, 2003 and 2002 and the
consolidated results of their operations and their cash flows for the years
ended December 31, 2003 and 2002 in conformity with accounting principles
generally accepted in the United States of America.
/s/ EISNER LLP
New York, New York
February 27, 2004
F-2
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
ASSETS
December 31,
----------------------
2003 2002
--------- ---------
CURRENT ASSETS
Cash and cash equivalents ........................ $2,710,029 $3,184,599
Temporary investments............................. 1,615,751 4,151,787
Marketable securities ............................ 6,098,986 882,243
Accounts receivable, net of allowance for doubtful
accounts of $27,000 and $25,500, respectively 1,007,055 704,560
Inventories ...................................... 1,093,312 1,037,315
Prepaid expenses and other current assets ........ 264,978 342,476
Deferred income taxes ............................ 207,817 297,774
---------- ----------
Total current assets ............... 12,997,928 10,600,754
---------- ----------
PROPERTY, PLANT AND EQUIPMENT
Land ............................................. 69,000 69,000
Factory equipment and fixtures ................... 2,825,125 2,738,110
Building and improvements ........................ 2,068,752 2,045,588
Waste disposal system ............................ 133,532 133,532
---------- ----------
5,096,409 4,986,230
Less accumulated depreciation .................... 4,070,158 3,880,660
---------- ----------
1,026,251 1,105,570
---------- ----------
OTHER ASSETS
Processes and patents, net of accumulated
amortization of $981,732 and $981,341,
respectively .................................. 65 456
Other ............................................ 700 700
---------- ----------
765 1,156
---------- ----------
$14,024,944 $11,707,480
========== ==========
See notes to financial statements
F-3
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' EQUITY
December 31,
----------------------
2003 2002
-------- --------
CURRENT LIABILITIES
Dividends payable ............................ $ 737,736 $ 488,114
Accounts payable ............................. 309,921 188,868
Accrued expenses ............................. 350,769 345,407
--------- ---------
Total current liabilities ............... 1,398,426 1,022,389
--------- ---------
DEFERRED INCOME TAXES ............................ 10,000 10,000
--------- ---------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, $.10 par value; 10,000,000
shares authorized; 4,984,439 and 4,943,339
shares issued, respectively; and 4,922,239
4,881,139 outstanding, respectively ........ 498,444 494,334
Capital in excess of par value................. 3,717,160 3,538,423
Accumulated other comprehensive loss........... (30,614) (55,776)
Retained earnings ............................. 8,791,158 7,057,740
Treasury stock, at cost; 62,200 shares ........ (359,630) (359,630)
---------- ----------
12,616,518 10,675,091
---------- ----------
$14,024,944 $11,707,480
========== ==========
See notes to financial statements
F-4
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
Year ended December 31,
-------------------------
2003 2002
----------- -----------
Revenue
Net sales ....................... $11,157,423 $ 9,091,416
---------- ---------
Costs and expenses
Cost of sales ................... 5,060,616 4,896,637
Operating expenses .............. 2,455,240 2,303,030
---------- ---------
7,515,856 7,199,667
---------- ---------
Income from operations ..... 3,641,567 1,891,749
Other income (expense)
Investment income................ 168,867 192,132
Gain on sale of assets........... 500 79
Other expense (23) (114)
---------- ---------
Income before income taxes . 3,810,911 2,083,846
Provision for income taxes .......... 1,339,757 662,341
---------- ---------
Net Income ................. $ 2,471,154 $ 1,421,505
========== =========
Earnings per common share (basic
and diluted)..................... $ .50 $ .29
========== =========
Weighted average shares-basic ....... 4,898,456 4,878,401
========== =========
Weighted average shares-diluted ..... 4,914,412 4,888,958
========== =========
See notes to financial statements
F-5
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
AND COMPREHENSIVE INCOME
Years ended December 31, 2002 and 2003
Accumulated
Common stock Capital in other
----------------------- excess of comprehensive Retained Treasury Comprehensive
Shares Amount par value income (loss) earnings stock Total income
--------- ----------- ---------- ------------- --------- -------- --------- ------------
Balance, December 31, 2001 4,932,639 $ 493,264 $ 3,492,518 $ (24,024) $ 6,124,349 $(359,630) $9,726,477
Issuance of common stock in
connection with exercise
of stock options ........... 10,700 1,070 34,905 35,975
Tax Benefit from exercise of
stock options .............. 11,000 11,000
Unrealized loss on marketable
securities, net of deferred
income tax benefit of
$22,562 .................... (31,752) (31,752) $ (31,752)
Net income .................... 1,421,505 1,421,505 1,421,505
Dividends declared ............ (488,114) (488,114)
---------
Comprehensive income $1,389,753
--------- --------- ----------- ---------- ---------- ---------- ---------- =========
Balance, December 31, 2002 4,943,339 494,334 3,538,423 (55,776) 7,057,740 (359,630) 10,675,091
Issuance of common stock in
connection with exercise
of stock options ........... 41,100 4,110 141,737 145,847
Tax Benefit from exercise of
stock options .............. 37,000 37,000
Unrealized loss on marketable
securities, net of deferred
income tax of $14,880 ...... 25,162 25,162 $ 25,162
Net income .................... 2,471,154 2,471,154 2,471,154
Dividends declared ............ (737,736) (737,736)
---------
Comprehensive income $2,496,316
--------- --------- ----------- ---------- ---------- ---------- ---------- =========
Balance, December 31, 2003 4,984,439 $ 498,444 $ 3,717,160 $ (30,614) $ 8,791,158 $(359,630) $12,616,518
========= ========= =========== ========== ========== ========== ==========
See notes to financial statements
F-6
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year ended December 31,
-----------------------
2003 2002
--------- ---------
Cash flows from operating activities
Net income ....................................... $2,471,154 $1,421,505
Adjustments to reconcile net income to net cash
provided by operating activities
Depreciation and amortization ................ 197,889 244,766
Amortization of bond premium.................. 5,916 12,224
Net gain on sale of equipment ................ (500) (79)
Provision for (recovery of) bad debts......... 14,479 (27,187)
Tax Benefit from exercise of stock options ... 37,000 11,000
Deferred income taxes ........................ 75,077 4,612
Provision for inventory obsolescence ......... 147,000 -
Increase (decrease) in cash resulting from
changes in operating assets and liabilities
Accounts receivable ..................... (316,974) 167,015
Inventories ............................. (202,997) 148,220
Prepaid expenses and other assets ....... 77,498 (14,252)
Accounts payable ........................ 121,053 (24,860)
Accrued expenses and taxes payable ...... 5,362 1,103
--------- ---------
Net cash provided by operating activities ... 2,631,957 1,944,067
--------- ---------
Cash flows from investing activities
Acquisition of plant and equipment................ (118,179) (131,650)
Proceeds from the sale of plant and equipment..... 500 14,500
Net decrease in temporary investments............. 2,536,036 213,327
Purchase of marketable securities................. (5,862,617) (4,433)
Proceeds from sale of marketable securities....... 680,000 -
-------- --------
Net cash (used in) provided by investing
activities ................................ (2,764,260) 91,744
-------- --------
Cash flows from financing activities
Proceeds from exercise of stock options .......... 145,847 35,975
Dividends paid ................................... (488,114) (487,044)
-------- --------
Net cash used in financing activities ....... (342,267) (451,069)
-------- --------
Net (decrease) increase in cash and cash equivalents.. (474,570) 1,584,742
Cash and cash equivalents, beginning of year ......... 3,184,599 1,599,857
--------- ---------
Cash and cash equivalents, end of year ............... $2,710,029 $3,184,599
========= =========
See notes to financial statements
F-7
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2003 and 2002
NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business
United-Guardian, Inc. (the "Company") is a Delaware corporation that
operates in two business segments: (1) the Guardian Laboratories Division
conducts research, product development, manufacturing and marketing of
pharmaceuticals, cosmetics, health care products, medical devices and
proprietary industrial products, and (2) the Eastern Chemical Corporation
subsidiary distributes a line of fine organic chemicals, research
chemicals, test solutions, indicators, dyes and reagents. Two major product
lines, Lubrajel and Renacidin, included in the Guardian Laboratories
Division, accounted for approximately 83% and 78% of consolidated sales,
respectively, for each of the years ended December 31, 2003 and 2002, with
Lubrajel accounting for 67% and 61%, and Renacidin accounting for 16% and
17% of consolidated sales for the years ended December 31, 2003 and 2002,
respectively.
Principles of Consolidation
The consolidated financial statements of the Company include the accounts
of United-Guardian, Inc. and its wholly-owned subsidiaries, Eastern
Chemical Corporation and Paragon Organic Chemicals, Inc. (a purchasing
agent for Eastern). All inter-company accounts and transactions have been
eliminated.
Revenue Recognition
The Company recognizes revenue as products are shipped and collections are
reasonably assured and title passes to customers.
Cash and Cash Equivalents
For financial statement purposes the Company considers as cash equivalents
all highly liquid investments with an original maturity of three months or
less.
Dividends
On December 3, 2003 the Company declared a cash dividend of $.15 per share
payable on January 5, 2004 to stockholders of record as of December 15,
2003 aggregating $737,736. On December 4, 2002, the Company declared a
dividend of $.10 per share payable on January 8, 2003 to stockholders of
record as of December 20, 2002 aggregating $488,114.
F-8
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE A (continued)
Statements of Cash Flows
Cash payments for income taxes were $1,135,025 and $611,630 for the years
ended December 31, 2003 and 2002, respectively. There were no cash payments
for interest during the years ended December 31, 2003 and 2002. Divided
payable of $737,736 was paid in January, 2004.
Marketable Securities and Temporary Investments
Marketable securities include investments in equity mutual funds,
government securities and corporate bonds which are classified as
"Available for Sale" securities and are reported at their fair values.
Unrealized gains and losses on "Available for Sale" securities are reported
as accumulated other comprehensive income (loss) in stockholders' equity,
net of the related tax effects. Investment income is recognized when
earned. Realized Gains and Losses on sales of investments are determined on
a specific identification basis. Fair values are based on quoted market
prices.
Temporary investments consist of certificates of deposit that mature in one
year or less.
Inventories
Inventories are valued at the lower of cost or current market value. Cost
is determined using the average cost method (which approximates FIFO).
Inventory costs include material, labor and factory overhead.
Property, Plant and Equipment
Property, plant and equipment are carried at cost, less accumulated
depreciation. Major replacements and betterments are capitalized while
routine maintenance and repairs are expensed as incurred. Assets are
depreciated under both accelerated and straight-line methods. Depreciation
charged to income as a result of using accelerated methods was not
materially different than that which would result from using the
straight-line method for all periods presented. Certain factory equipment
and fixtures are constructed by the Company using purchased materials and
in-house labor. Such assets are capitalized and depreciated on a basis
consistent with the Company's purchased fixed assets.
F-9
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE A (continued)
Estimated useful lives are as follows:
Factory equipment and fixtures 5 - 7 years
Building 40 years
Building improvements Lesser of useful life or 20 years
Waste disposal system 7 years
Processes and Patents
Processes and patents are amortized over periods ranging from 5 to 15
years. Amounts are shown net of accumulated amortization.
Long-Lived Assets
It is the Company's policy to evaluate and recognize an impairment to its
long-lived assets if it is probable that the recorded amounts are in excess
of anticipated undiscounted future cash flows.
Fair Value of Financial Instruments
The Company has estimated the fair value of financial instruments using
available market information and other valuation methodologies in
accordance with Statement of Financial Accounting Standards ("SFAS") No.
107, "Disclosures About Fair Value of Financial Instruments." Management of
the Company believes that the fair value of financial instruments,
consisting of cash, temporary investments, accounts receivable, accounts
payable, dividends payable and accrued expenses approximates their carrying
value due to their short payment terms.
Concentration of Credit Risk
Accounts receivable potentially expose the Company to concentrations of
credit risk. The Company routinely addresses the financial strength of its
customers and, as a consequence, believes that its accounts receivable
credit risk exposure is limited. For each of the years ended December 31,
2003 and 2002, one customer accounted for revenues aggregating 40% and 32%
respectively. At December 31, 2003, two and one customers, respectively,
had accounts receivable balances aggregating 46% and 35%, respectively.
F-10
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE A (continued)
Income Taxes
Deferred tax assets and liabilities reflect the future tax consequences of
the differences between the financial reporting and tax bases of assets and
liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse. Deferred tax assets are reduced by a
valuation allowance when, in the opinion of management, it is more likely
than not that some portion or all of the deferred tax assets will not be
realized.
Research and Development
The Company's research and development expenses, included in operating
expenses, are recorded in the year incurred. Research and development
expenses were approximately $403,000 and $348,000 for the years ended
December 31, 2003 and 2002, respectively.
Shipping and Handling Costs
Shipping and handling costs are classified in operating expenses in the
accompanying consolidated statements of income. Shipping and handling costs
were approximately $115,000 and $107,800 for the years ended December 31,
2003 and 2002, respectively.
Advertising Costs
Advertising costs are expensed as incurred. During 2003 and 2002 the
Company incurred $100,261 and $74,579 of advertising costs, respectively.
Stock-Based Compensation
At December 31, 2003, the Company had two stock-based employee compensation
plans, which are described more fully in Note F. As permitted under SFAS
NO. 148, Accounting for Stock-Based Compensation-Transition and Disclosure,
which amended SFAS NO. 123 Accounting for Stock-Based Compensation, the
Company has elected to continue to follow the intrinsic value method in
accounting for its stock-based employee compensation arrangements as
defined by Accounting Principle Board Opinion ("APB") No. 25, "Accounting
for Stock Issued to Employees", and related interpretations including
Financial Accounting Standards Board Interpretation No. 44, "Accounting for
Certain Transactions involving Stock Compensation, and interpretations of
APB No. 25". The following table illustrates the effect on net income and
earnings per share if the company had applied the fair value recognition
provisions of SFAS No.123 to stock-based employee compensation.
F-11
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
Year Ended December 31
-------------------------
2003 2002
--------- ---------
Reported net income .................... $ 2,471,154 $ 1,421,505
Stock-based employee compensation
expense included in reported net
income, net of related tax effect ..... 0 0
Stock-based employee compensation
determined under the fair value based
method, net of related tax effect...... (18,743) (11,676)
--------- ---------
Pro forma net income..................... $ 2,452,411 $ 1,409,829
========= =========
Earnings per share (basic and diluted)
As reported ....................... $ .50 $ .29
======== ========
Pro forma ......................... $ .50 $ .29
======== ========
In 2002, 22,800 stock options were granted under the EISOP (Employee
Incentive Stock Option Plan) and 16,000 stock options were granted under
the NSSOPD (Non-Statutory Stock Option Plan). No stock options were granted
under either plan in 2003.
The fair value of each option on the date of grant is estimated using the
Black-Scholes option-pricing model with a volatility of 45% for 2002,
expected life of options of three to five years, risk free interest rates
of 2.31% and 3.13% and a dividend yield of 2%. The weighted average fair
value of options granted during the year ended December 31, 2002 was $1.15.
There were no grants under either plan in 2003.
Earnings Per Share Information
Basic earnings per share is computed by dividing net income by the weighted
average number of common shares outstanding during the year. Diluted
earnings per share includes the dilutive effect of outstanding stock
options.
Use of Estimates
In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required
F-12
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE A (continued)
to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the financial statements and revenues and
expenses during the reporting period. Actual results could differ from
those estimates. Such estimated items include allowance for bad debt,
reserve for inventory obsolescence, and allocation of overhead.
Segment Reporting
SFAS No. 131, "Disclosures About Segments of an Enterprise and Related
Information," requires that the Company disclose certain information about
its business segments defined as "components of an enterprise about which
separate financial information is available that is evaluated regularly by
the chief operating decision maker in deciding how to allocate resources
and in assessing performance."
New Accounting Pronouncements
In June 2002, the FASB issued FAS No. 146, Accounting for Costs Associated
with Exit or Disposal Activities ("FAS 146"). This statement requires
recording costs associated with exit or disposal activities at their fair
values when a liability has been incurred. Under previous guidance, certain
exit costs were accrued upon management's commitment to an exit plan.
Adoption of this Statement was required with the beginning of fiscal year
2003. The Company adopted this statement on January 1, 2003. The adoption
of FAS 146 did not have any impact on the Company's financial position or
results of operations.
Effective January 1, 2003, the Company adopted the recognition and
measurement provisions of FASB Interpretation No. 45), Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others ("Interpretation 45"). This
interpretation elaborates on the disclosures to be made by a guarantor in
interim and annual financial statements about the obligations under certain
guarantees. Interpretation 45 also clarifies that a guarantor is required
to recognize, at the inception of a guarantee, a liability for the fair
value of the obligation undertaken in issuing the guarantee. The initial
recognition and initial measurement provisions of this interpretation are
applicable on a prospective basis to guarantees issued or modified after
December 31, 2002. The Company does not currently provide significant
guarantees on a routine basis. As a result, this interpretation has not had
a material impact on the Company's financial statements.
In January 2003, the FASB issued Interpretation No. 46, Consolidation of
Variable Interest Entities--an Interpretation of ARB No. 51 ("FIN 46"),
which addresses consolidation of variable interest entities. FIN 46 expands
the criteria for consideration in determining whether a variable interest
entity should be consolidated by a business entity, and requires existing
unconsolidated variable interest entities (which include, but are not
limited to, Special Purpose Entities, or SPEs) to be consolidated by their
F-13
primary beneficiaries if the entities to not effectively disperse risks
among parties involved. On October 9, 2003, the FASB issued Staff Position
No. 46-6 which deferred the effective date for applying the provisions of
FIN 46 for interests held by public entities in variable interest entities
or potential variable interest entities created before February 1, 2003. On
December 24, 2003, the FASB issued a revision to FIN 46. Under the revised
interpretation, the effective date was delayed to periods ending after
March 15, 2004 for all variable interest entities, other an SPEs. The
adoption of FIN 46 is not expected to have an impact on the Company's
financial condition, results of operations or cash flows.
In May 2003, The FASB issued FAS No. 149, Amendment of Statement 133 on
Derivative Instruments and Hedging Activities ("FAS 149"). FAS 149 amends
and clarifies accounting for derivative instruments, including certain
derivative instruments embedded in other contracts, and for hedging
activities under FAS No. 133. FAS 149 is effective for contracts entered
into or modified after June 30, 2003, and for hedging relationships
designated after June 30, 2003. The adoption of FAS 149 did not have any
impact on the Company's financial position or results of operations.
In May 2003, the FASB issued FAS No. 150, Accounting for Certain Financial
Instruments with Characteristics of Both Liabilities and Equity ("FAS
150"). FAS 150 establishes standards for how an issuer classifies and
measures certain financial instruments with characteristics of both
liabilities and equity. It requires that an issuer classify a financial
instrument that is within its scope as a liability (or an asset in some
circumstances). Many of those instruments were previously classified as
equity. FAS 150 is effective for financial instruments entered into or
modified after May 31, 2003, and otherwise is effective at the beginning of
the first interim period beginning after June 15, 2003. It is to be
implemented by reporting the cumulative effect of a change in accounting
principle for financial instruments created before the issuance date of the
statement and still existing at the beginning of the interim period of
adoption. Restatement is not permitted. The Company adopted the provisions
of FAS 150 effective July 1, 2003. The adoption of FAS 150 did not have any
impact on the Company's financial position or results of operations.
NOTE B - MARKETABLE SECURITIES
Marketable securities at December 31, 2003 and 2002 were as follows:
Unrealized
Cost Fair Value Gain/(Loss)
-------- ---------- ----------
December 31, 2003
-----------------
Available for sale:
U.S. Treasury and agencies $3,817,880 $3,810,829 $( 7,051)
Corporate debt securities 2,040,522 2,037,035 ( 3,487)
Mutual funds 289,498 251,122 (38,376)
--------- --------- ------
$6,147,900 $6,098,986 $(48,914)
========= ========= ======
F-14
December 31, 2002
-----------------
Held to maturity:
Corporate debt securities $ 685,916 $ 685,916 $ 0
Available for sale:
Mutual funds 285,283 196,327 (88,956)
------- ------- ------
$ 971,199 $ 882,243 $(88,956)
======= ======= ======
NOTE C - INVENTORIES
Inventories consist of the following:
December 31,
----------------------------
2003 2002
----------- -----------
Raw materials and work-in-process ...... $ 225,443 $ 269,067
Finished products and fine chemicals ... 867,869 768,248
---------- ----------
$1,093,312 $1,037,315
========== ==========
NOTE D - NOTES PAYABLE - BANKS
The Company has a line of credit agreement with a bank which provides for
borrowings of up to $700,000 and expires on May 31, 2004. It is the
Company's intention to renew the line of credit agreement before it
expires. Interest under the line is at the bank's prime rate plus 1/2%. The
line of credit agreement contains financial covenants relating to minimum
net worth, working capital, current ratio, a debt to capitalization ratio
and maintenance of compensating balances. There were no outstanding
borrowings at December 31, 2003 and 2002.
F-15
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE E - INCOME TAXES
The provision for income taxes consists of the following:
Year ended December 31,
--------------------------
2003 2002
--------- ---------
Current
Federal .............................. $1,085,789 $ 562,310
State ................................ 178,891 95,419
--------- ---------
1,264,680 657,729
--------- ---------
Deferred
Federal .............................. 65,013 3,997
State ................................ 10,064 615
--------- ---------
75,077 4,612
--------- ---------
Total provision for income taxes ... $1,339,757 $ 662,341
========= =========
The following is a reconciliation of the Company's effective income tax
rate to the Federal statutory rate:
Year ended December 31,
--------------------------------
2003 2002
-------------- --------------
(000's) % (000's) %
------- --- ------- ---
Income taxes at statutory Federal income
tax rate .............................. $1,296 34% $ 709 34%
State income taxes, net of Federal benefit 125 3 63 3
Foreign Sales Exclusion .................. (68) (2) (68) (3)
Nondeductible expenses.................... 10 - 2 -
Other, net ............................... (23) - (44) (2)
----- ---- ----- ----
Actual income tax expense ................ $1,340 35% $ 662 32%
===== ==== ===== ====
F-16
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE E (continued)
During 2003 and 2002, the Company recognized the tax benefit of the
Foreign Sales exclusion.
The tax effects of temporary differences which comprise the deferred tax
assets and liabilities are as follows:
December 31
------------------------
2003 2002
----------- ------------
Deferred tax assets
Current
-------
Accounts receivable .................... $ 10,071 $ 19,652
Unrealized loss on marketable securities 18,300 33,180
Inventories ............................ 81,687 136,518
Accrued Expenses ....................... 62,643 82,620
Other................................... 35,116 25,804
--------- ---------
207,817 297,774
--------- ---------
Deferred tax liabilities
Non-current
-----------
Other .................................. (10,000) (10,000)
--------- ---------
(10,000) (10,000)
--------- ---------
Net deferred tax asset ..................... $ 197,817 $ 287,774
========= =========
NOTE F - BENEFIT PLANS
Pension Plan
The Company has a noncontributory defined benefit pension plan which covers
substantially all of its employees. Benefits are based on years of service
and employees' compensation prior to retirement. Amounts are funded in
accordance with the requirements of ERISA (Employee Retirement Income
Security Act of 1974) and the plan is administered by a trustee who is
responsible for payments to retirees. The plan assets primarily consist of
cash equivalents, bonds, commercial paper and mortgage-backed securities,
and are recorded at fair value within the plan.
F-17
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE F (continued
The following table sets forth the plan's
funded status:
Year ended December 31,
----------------------
2003 2002
--------- ---------
Change in Benefit Obligation:
Projected benefit obligation at beginning of year... $2,125,941 $1,909,099
Service cost........................................ 83,291 76,115
Interest cost....................................... 134,820 122,743
Actuarial loss...................................... 63,899 42,067
Other............................................... 0 1,042
Benefits paid....................................... (47,552) (25,125)
--------- ---------
Projected benefit obligation at end of year....... $2,360,399 $2,125,941
========= =========
Change in Plan Assets:
Fair value of plan assets at beginning of year... $1,754,025 $1,559,145
Actual return on plan assets..................... 147,042 115,805
Employer contributions........................... 103,741 104,200
Benefits paid.................................... (47,552) (25,125)
--------- ---------
Fair value of plan assets at end of year....... $1,957,256 $1,754,025
========= =========
Reconciliation of Funded Status:
Funded status (underfunded)...................... $ (403,143) $ (371,916)
Unrecognized net actuarial loss.................. 410,008 369,604
Unrecognized prior service cost.................. 54,381 61,842
--------- ---------
Prepaid benefit cost........................... $ 61,246 $ 59,530
========= =========
The net periodic benefit cost includes the following components:
Year ended December 31,
-------------------------
2003 2002
Components of net periodic benefit cost: ----------- -----------
Service cost..................................... $ 83,291 $ 76,115
Interest cost.................................... 134,820 122,743
Expected return on plan assets................... (139,295) (124,245)
Recognized net actuarial loss.................... 15,748 13,637
Amortization of transition obligation............ 0 4,298
Amortization of prior service cost............... 7,461 7,356
--------- ---------
Net periodic benefit cost..................... $ 102,025 $ 99,904
========= =========
F-18
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE F (continued)
Weighted-average assumptions as of December 31:
2003 2002
----------- ----------
Discount rate...................................... 6.00% 6.50%
Expected long term rate of return.................. 7.00% 8.00%
Weighted average rate of compensation increase..... 5.69% 5.51%
Amortization method................................ Straight-Line Straight-Line
401(k) Plan
The Company maintains a 401(k) Plan for all of its eligible employees.
Under the plan, employees may defer up to 15% of their weekly pay as a
pretax investment in a savings plan. In addition, the Company makes a
contribution of 50% of the first 4% of each employee's elective deferral up
to a maximum employer contribution of 2% of weekly pay. Employees become
fully vested in Company contributions after one year of employment. 401(k)
Company contributions were approximately $39,000 and $38,000 for the years
ended December 31, 2003 and 2002, respectively.
Stock Option Plans
The Company maintained two stock option plans, the 1993 Employee Incentive
Stock Option Plan ("EISOP") and the Non-Statutory Stock Option Plan for
Directors ("NSSOPD"), each of which provided for the issuance of up to
100,000 shares of common stock at the market price on the date of the
grant. Such options were exercisable either upon grant or after a waiting
period specified in the agreement. The Company has adopted only the
disclosure provisions of SFAS No. 123, "Accounting for Stock-based
Compensation." It applies APB Opinion No. 25, "Accounting for Stock Issued
to Employees," and related Interpretations in accounting for its plans.
Accordingly, no compensation costs have been recognized for either plan.
Both of these stock option plans expired in 2003.
F-19
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE F (continued)
The following summarizes the stock option transactions under both plans:
Number Weighted average
EISOP outstanding exercise price
----- ------------ -------
Options outstanding January 1, 2002.... 31,400 3.59
Granted 22,800 3.54
Exercised (8,700) 3.66
------
Options outstanding at December 31, 2002 45,500 3.55
-------
Options exercisable at December 31, 2002 34,700 3.54
-------
Expired (200) 3.51
Exercised (35,100) 3.58
------
Options outstanding and exercisable at
December 31, 2003................. 10,200 3.44
======
Available for grant at December 31, 2003 0
======
NSSOPD
------
Options outstanding at January 1, 2002.. 8,000 $2.55
Forfeited (2,000) 3.00
Exercised (2,000) 2.06
Granted 16,000 3.51
------
Options outstanding at December 31, 2002 20,000 3.41
------
Options exercisable at December 31, 2002 4,000 3.00
------
Exercised (6,000) 3.34
------
Options outstanding and exercisable at
December 31, 2003 14,000 3.44
======
Available for grant at December 31, 2003 0
======
Summarized information about stock options outstanding under the two plans at
December 31, 2003 is as follows:
F-20
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE F (continued)
Options Outstanding Options Exercisable
--------------------------------------------- -------------------------
Number of Shares Weighted Weighted Number of Shares Weighted
Range of Outstanding Average Average Exercisable Average
Exercise at Remaining Exercise at Exercise
Prices December 31,2003 Contractual Life Price December 31,2003 Price
------------ ---------------- ---------------- -------- ---------------- --------
EISOP
-----
$2.06 - $3.30 3,300 2.02 $3.07 3,300 $3.07
$3.51 - $3.86 6,900 7.45 3.61 6,900 3.61
------------- ------ ---- ----- ------ -----
$2.06 - $3.86 10,200 5.69 $3.44 10,200 $3.44
NSSOPD
--------
$3.00 2,000 .30 $3.00 2,000 $3.00
$3.51 12,000 3.90 3.51 12,000 3.51
------------- ------ ---- ---- ----- -----
$3.00 - $3.51 14,000 3.39 $3.44 14,000 $3.44
NOTE G - EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted
earnings per share at December 31, 2003 and 2002:
2003 2002
--------- ---------
Numerator:
Net earnings $ 2,471,154 $ 1,421,505
--------- ---------
Denominator:
Denominator for basic earnings
per share (weighted average shares) 4,898,456 4,878,401
Effect of dilutive securities:
Employee stock options 15,956 10,557
--------- ---------
Denominator for diluted earnings per
share (adjusted weighted-average
shares) and assumed conversions 4,914,412 4,888,958
========= =========
Basic and diluted earnings per share $ 0.50 $ 0.29
========= =========
F-21
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2002 and 2001
NOTE G (continued)
Options to purchase 8,500 shares of the Company's common stock have been
excluded from the computation of diluted earnings per share in 2002 as
their inclusion would be antidilutive. In 2003 there were no options
excluded from the computation of diluted earnings per share.
NOTE H - NATURE OF BUSINESS AND SEGMENT INFORMATION
The Company has the following two reportable business segments: Guardian
Laboratories and Eastern Chemical. The Guardian segment conducts research,
development and manufacturing of pharmaceuticals, medical devices,
cosmetics, products and proprietary specialty chemical products. The
Eastern segment distributes fine chemicals, solutions, dyes and reagents.
The accounting policies used to develop segment information correspond to
those described in the summary of significant accounting policies. Segment
earnings or loss is based on earnings or loss from operations before income
taxes. The reportable segments are distinct business units operating in
different industries. They are separately managed, with separate marketing
and distribution systems. The following information about the two segments
is for the years ended December 31, 2003 and 2002.
2003 2002
---------------------------------- ----------------------------------
GUARDIAN EASTERN TOTAL GUARDIAN EASTERN TOTAL
------------ ----------- ----------- ------------ ----------- -----------
Revenues from external customers $10,068,977 $ 1,088,446 $11,157,423 $ 7,938,428 $ 1,152,988 $ 9,091,416
Depreciation and amortization 84,510 - 84,510 130,037 - 130,037
Segment income before income
tax expense 3,798,573 8,421 3,806,994 2,153,927 (82,656) 2,071,271
Segment assets 2,189,252 381,553 2,570,805 2,405,390 668,936 3,074,326
Capital expenditure 72,039 - 72,039 53,189 - 53,189
Reconciliation to Consolidated Amounts
Income before income taxes
----------------------------
Total income for reportable segments $ 3,806,994 $ 2,071,271
Other income, net 169,344 192,097
Corporate headquarters expense (165,427) (179,522)
--------- ---------
Consolidated income before income taxes $ 3,810,911 $ 2,083,846
========= =========
Assets
------
Total assets for reportable segments $ 2,570,805 $ 3,074,326
Corporate headquarters 11,454,139 8,633,154
---------- ----------
Total consolidated assets $14,024,944 $11,707,480
========== ==========
F-22
UNITED-GUARDIAN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
December 31, 2003 and 2002
NOTE H (continued)
Other Significant Items
-----------------------
2003 2002
-------------------------------------- --------------------------------------
Segment Consolidated Segment Consolidated
Totals Corporate Totals Totals Corporate Totals
---------- ----------- ------------ ---------- ----------- ------------
Capital expenditures 72,039 46,140 118,179 53,189 78,461 131,650
Depreciation and amortization 84,510 119,295 203,805 130,037 126,953 256,990
Geographic Information
----------------------
2003 2002
------------------------- ------------------------
Long-Lived Long-Lived
Revenues Assets Revenues Assets
---------- ----------- ---------- -----------
United States $ 5,676,595 $ 1,026,316 $ 4,633,847 $ 1,106,026
France 1,335,734 1,179,919
Other countries 4,145,094 3,277,650
---------- --------- ---------- ---------
$11,157,423 $ 1,026,316 $ 9,091,416 $ 1,106,026
========== ========= ========== =========
Major Customers
---------------
Customer A (Guardian) $ 4,422,424 $ 2,916,638
Customer B (Guardian) 1,096,923 -
All other customers 5,638,076 6,174,778
---------- ----------
$11,157,423 $ 9,091,416
========== ==========
NOTE I - CONTINGENCIES
While the Company has claims that arise from time to time in the ordinary
course of its business, the Company is not currently involved in any
material claims. The settlement of such claims has not had a material
adverse effect on the Company's financial position and results of
operations.
F-23
NOTE J - RELEATED PARTY TRANSACTIONS
During the years ended December 31, 2003 and 2002 the Company paid to Henry
Globus, a former officer and current Director of the Company, $18,210 and
$17,748 respectively, for consulting services in accordance with his
employment termination agreement of 1998.
During the years ended December 31, 2003 and 2002 the Company paid to
Bonamassa , Maietta, and Cartelli, LLP, $9,000 and $10,500 respectively for
accounting services. Lawrence Maietta, a partner in Bonamassa , Maietta,
and Cartelli, LLP, is currently a Director of the Company.
F-24
EXHIBIT 31.1
------------
SECTION 302 CERTIFICATION
I, Alfred R. Globus, Chief Executive Officer of United-Guardian, Inc.,
certify that:
1. I have reviewed this annual report on Form 10-KSB of United-Guardian, Inc.
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: March 23, 2004 /s/ Alfred R. Globus
-----------------------
Alfred R. Globus
Chief Executive Officer
EXHIBIT 31.2
------------
SECTION 302 CERTIFICATION
I, Kenneth H. Globus, President and Chief Financial Officer of
United-Guardian, Inc., certify that:
1. I have reviewed this annual report on Form 10-KSB of United-Guardian, Inc.
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: March 23, 2004 /s/ Kenneth H. Globus
--------------------------
Kenneth H. Globus
President and Chief Financial Officer
EXHIBIT 32.1
------------
UNITED-GUARDIAN, INC.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of United-Guardian, Inc. (the
"Registrant") on Form 10-KSB for the year ended December 31, 2003, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Alfred R. Globus, Chief Executive Officer of the Registrant, hereby certify,
pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.
Date: March 23, 2004 /s/ Alfred R. Globus
--------------------------
Alfred R. Globus
Chief Executive Officer
EXHIBIT 32.2
------------
UNITED-GUARDIAN, INC.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of United-Guardian, Inc. (the
"Registrant") on Form 10-KSB for the year ended December 31, 2003, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Kenneth H. Globus, President and Chief Financial Officer of the Registrant,
hereby certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to
section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.
Date: March 23, 2004 /s/ Kenneth H. Globus
--------------------------
Kenneth H. Globus
President and Chief Financial Officer